Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SSS11 in Healthy Volunteers
NCT04047394Phase 1Unknown
- Sponsor
- 3SBio
- Start
- Oct 2019
- Primary completion
- Oct 2022
- Modality
- Therapeutic Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegadricase in gout, sponsored by 3SBio. Primary endpoints: Adverse events (AEs), Dose Limiting Toxicity and 3 more. Status: unknown.
02
Drugs
pegadricase
03
Conditions
gout
Beyond the preview
Go deeper on NCT04047394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047394.